Table 2. Univariate analysis of factors associated with survival and recurrence.
| Variables | OS | DFS | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Age, y (>50 vs. ≤50) | 0.985 (0.502–1.931) | 0.964 | 0.762 (0.359–1.619) | 0.479 |
| Gender (female vs. male) | 1.405 (0.761–2.594) | 0.276 | 1.531 (0.755–3.107) | 0.238 |
| Location (rectal vs. colon) | 1.039 (0.561–1.925) | 0.903 | 1.182 (0.584–2.391) | 0.642 |
| Tumor size, cm (>5 vs. ≤5) | 0.596 (0.212–1.672) | 0.325 | 0.487 (0.148–1.601) | 0.236 |
| Invasion depth (T3-T4 vs. T1-T2) | 3.174 (0.979–10.285) | 0.054 | 2.084 (0.729–5.959) | 0.171 |
| Lymph node metastasis (N1-N2 vs. N0) | 3.162 (1.656–6.039) | 0.000 | 2.585 (1.265–5.283) | 0.009 |
| Distant metastasis (M1 vs. M0) | 5.977 (3.216–11.106) | 0.000 | ||
| TNM stage (III-IV vs. I-II) | 7.573 (3.178–18.048) | 0.000 | ||
| Tumor histology type (adenocarcinoma vs. mucinous/signet-ring) | 1.263 (0.560–2.850) | 0.574 | 0.451 (0.108–1.890) | 0.276 |
| Tumor degree of differentiation (poor vs. well/moderate) | 1.923 (1.041–3.554) | 0.037 | 1.122 (0.528–2.382) | 0.765 |
| KRAS status (mutation vs. wild type) | 1.128 (0.584–2.178) | 0.720 | 2.037 (0.997–4.160) | 0.051 |
| MSI status (MSI vs. MSS) | 1.774 | 0.115 | 2.724 | 0.028 |
| (0.869–3.620) | (1.114–6.657) | |||
| Expression of BIRC6 (positive vs. negative) | 3.170 (1.512–6.647) | 0.002 | 2.673 (1.230–5.812) | 0.013 |
Bold items have been considered statistically significant. Cox proportional hazards regression model was used in univariate analysis. Patients with TNM stage IV tumors were excluded when analyzing disease-free survival. Abbreviations: 95% CI, 95% confidence interval; OS, overall survival; DFS, disease-free survival; TNM, tumor-node-metastasis; MSI, microsatellite instability; MSS, microsatellite stable.